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found (odds ratios of 1.02, 1.019, 1.70, 1.04, 0.99 with p-values 0.79, 
0.3, 0.21, 0.88, 0.25 respectively in univariate analysis). We tested 
also whether our hypothesis is confirmed for the subset of patients 
with pre-treatment dyspnea grade 0 or 1, 124 (83.2%) patients, as high 
levels of dyspnea may well be due to congestive heart failure 
irrespective of RCHT. The results show an even higher odds ratio, 4.33 
(p-value < 0.001, 95% CI: 1.76-10.67), of maximal dyspnea ≥ 2 for 
patients with cardiac comorbidity. 
Figure 1. Frequency of RILT (measured by a CTCv3.0 dyspnea score 
within 6 months from the beginning of RCHT), for patients 
with/without cardiac comorbidity. The hypothesis that the odds ratio 
for post-RCHT dyspnea grade >=2 for the cardiac vs. no-cardiac 
comorbidity patients is equal to 1 is rejected (odds ratio = 3.65, p-
value <0.001, 95% CI = 1.70-7.81), total number patients = 149. 
 
 
Conclusions: Our results suggest that cardiac comorbidity is an 
important candidate factor for developing RILT after definite 
(chemo)radiotherapy of lung cancer patients. Therefore this 
observation should be further researched and externally validated.  
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Purpose/Objective: Chemoradiotherapy (CRT) represents an actual 
treatment standard in limited disease small cell lung cancer (LD SCLC) 
and timing of thoracic irradiation (TRT) has been already the subject 
of randomised trials and meta-analyses. Several of them reported 
significantly improved overall survival (OS) when platinum-based early 
concurrent CRT is used. To investigate a correlation between CRT 
schedule and OS a temporal analysis of the multimodality treatment 
was performed in patients with LD SCLC. 
Materials and Methods: 182 patients with PS WHO 0-3 who 
successfully completed CRT were retrospectively reviewed. Thoracic 
radiation therapy (TRT) was applied in the concurrent or sequential 
mode. Influence of the treatment mode and interval of simultaneous 
treatment (IST) (IST – an interval in days when chemotherapy and TRT 
were applied simultaneously, including also time between 
chemotherapy cycles) on OS was analysed. 
Results: 70 (38%) patients were treated with concurrent and 112 (61%) 
with sequential CRT. Median survival (MS) for the entire cohort was 
536 days (95% CI: 462 – 609) without difference between the groups 
(concurrent 599 vs. sequential 532 days, p = 0.9, log-rank test). IST 
was 0 in 112 (61%) patients treated with sequential CRT whereas in 
the concurrent CRT group 29 (16%) and 42 (23%) patients showed an 
IST < 35 and >35, respectively. Patients with IST < 35 demonstrated a 
trend to better OS (MS: IST 0 vs. >35 vs. <35 was 533 vs. 448 vs. 1169 
days, p = 0.109, log-rank test). When patients treated with sequential 
CRT were excluded from the analysis, statistical difference in OS 
achieved significance (p = 0.021, log-rank test). In the multivariate 
analysis of patients treated with concurrent CRT, IST < 35 remained 
be significant variable correlating with better OS (p = 0.039, Cox 
regression). 
Conclusions: Temporal analysis of CRT schedule revealed that IST < 35 
can represent an important treatment-related parameter correlating 
with OS in patients with LD SCLC. By exceeding this interval we have 
seen no further improvement of OS due to concurrent application of 
the multimodality treatment. 
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Purpose/Objective: Delineation of the gross tumour volume (GTV) in 
esophageal cancer remains difficult. Moreover, to compensate for 
microscopic tumour spread, the current standard is to use relatively 
large margins (3-4 cm) from GTV to clinical target volume (CTV). The 
aim of this study was: (1) to analyse the accuracy of GTV delineation; 
(2) to analyse if the margins to the CTV were sufficient at pathologic 
examination after neo-adjuvant chemoradiotherapy (neo-CHRT), and: 
(3) to investigate if pathological findings after neo-CHRT influenced 
overall survival (OS).  
Materials and Methods: The study population was composed of 63 
esophageal cancer patients treated with neo-CHRT. In all patients, 
planning-CT scans were used combined with all diagnostic information 
to determine the GTV and CTV. During surgery, the GTV and CTV 
borders, as delineated on the planning-CT scans, were demarcated in 
situ at the esophagus in order to provide information regarding the 
exact location of macroscopic and microscopic tumour (see Figure). 
Demarcation points consisted of anatomical reference points that 
could be easily recognised both at CT and intraoperative (e.g. 
tracheal bifurcation, aortic arch, celiac trunk). To identify prognostic 
factors for OS, univariate and multivariate analysis were performed. 
Results: After resection, macroscopic residual tumour was found 
outside the GTV in 7 patients (11%). Microscopic residual tumour was 
located outside the CTV in nine patients (14%), in most cases caudally 
from the CTV. Three of these patients had an R1-resection, including 
2 with circumferential invasion and only 1 with invasion of the cranial 
and caudal borders. Six patients were partial responders, while three 
showed almost no response. The median follow up was 16.6 months 
(95% CI 14-19 months). In the univariate analysis, microscopic tumour 
extension outside the CTV, ypN+, lymphangio-invasion, perineural 
growth, lymph node ratio >0.10 and >5 positive lymph nodes were 
associated with worse OS. In the multivariate analysis, only 
microscopic tumour extension outside the CTV (HR 4.96, 95%CI 1.03-
15.36) and perineural growth (HR 5.77, 95%CI 1.27-26.13) were 
identified as independent adverse prognostic for OS. Without tumour 
outside the CTV the 1 year OS was 86% vs. 20% for patients with 
tumour outside the CTV (p=<0.01). 
Conclusions: Despite using advanced pre-RT imaging and neo-CHRT, 
(1) macroscopic tumour outside the GTV was found in 11% of the 
patients and (2) microscopic tumour foci outside the CTV in 14% of the 
cases (mainly caudally from the CTV). (3) Moreover, the presence of 
microscopic tumour spread beyond CTV borders had a significant and 
major adverse impact on OS. These findings emphasize the 
importance of accurate delineation of the GTV and indicate that 
currently used margins from GTV to CTV in particular in caudal 
direction are not sufficient which may adversely impact treatment 
outcome.  
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Purpose/Objective: The main weakness of the radiotherapy workflow 
is undoubtly the GTV delineation. It is therefore important to validate 
automated segmentation methods in 2D but even better in 3D. FDG 
uptake within a tumor, assessed with PET-imaging, can be used to 
automatically create a tumor contour using standardized uptake value 
(SUV) thresholding. It has already been shown that the tumor length 
measured in the surgical specimen correlates highly with a PET-based 
autocontour. The goal of this study was to validate the volume of an 
automatic generated PET-based tumor contour with pathology for 
rectal cancer. 
Materials and Methods: Eight patients diagnosed with non-locally 
advanced rectal cancer (NLARC), referred for pre-operative treatment 
